Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Lopez
V
V
Pinazo
I
I
Marti
N
N
Monteagudo
C
C
Jorda
E
E
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced / Q000175:diagnosis; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D009536:Niacinamide / Q000031:analogs & derivatives; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology*; D012871:Skin Diseases / Q000139:chemically induced* / Q000175:diagnosis; D012878:Skin Neoplasms / Q000473:pathology; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; C054368:fotemustine